 Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaqs Marketplace Rule 5550a2 for continued listing on the Nasdaq Capital Market. Accordingly, Nasdaq considers the matter closed. Gastroparesis is a debilitating, episodic condition that disproportionately affects adult women and is characterized by slow or delayed gastric emptying of the stomachs contents after meals, often resulting in flares of symptoms that include nausea, vomiting, abdominal pain and bloating. 